OBJECTIVES: In 2015, the Committee on Medicinal Products of the 37 Publics Hospitals of Paris (AP-HP) authorized the tender between two infliximab biosimilars (BIOSIM-INFLIX) and their originator (ORIGIN-INFLIX) only for naïve-patients, as the current French law does not allow the switch from originator biologics to biosimilars for pretreated-patients. A BIOSIM-INFLIX won the tender and two infliximab have been listed in the hospital drug formulary (HDF) of AP-HP since September 2015: BIOSIM-INFLIX for naive-patients and ORIGIN-INFLIX for pretreated-patients. This study analyzes the spread of BIOSIM-INFLIX and of ORIGIN-INFLIX in AP-HP. METHODS: Infliximab consumption and expenses data from AP-HP were analyzed over the January 2015 to May 2016 period to retrospectively assessed BIOSIM-INFLIX and ORIGIN-INFLIX market shares within all AP-HP hospitals. RESULTS: Infliximab expenses in AP-HP in the January-May 2016 period was down 7% compared to the January-May 2015 period (€15.2 vs. €16.3 million respectively), while infliximab consumption in volume globally increased by 12.3% between the two periods. The rise in infliximab consumption was offset by a negative price effect due to the competition of BIOSIM-INFLIX (-45% and -12.1% price discounts for BIOSIM-INFLIX and for ORIGIN-INFLIX respectively). In May 2016, infliximab products were used in 19 AP-HP hospitals and the BIOSIM-INFLIX uptakes in volume reached 29.9% (vs. 3.7% in France in 2015). However, BIOSIM-INFLIX uptakes are heterogeneous among AP-HP hospitals: >80% for 2 hospitals, between 60% and 30% for 5 hospitals, <20% for 12 hospitals. Two hospitals initially decide to only list the BIOSIM-INFLIX in their local HDF but recently returned back to meet patients’ expectations. CONCLUSIONS: Pending the development of a new law governing the substitution for treatment-naïve or pretreated patients receiving biologics in France, today the BIOSIM-INFLIX uptakes are depending on hospital decision-makers. The therapeutic indications in which BIOSIM-INFLIX and ORIGIN-INFLIX are used and the naive/pretreated status of patients have now to be explored.